Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma
NCT06045806Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Progression-Free Survival at 50 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06045806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045806.